Roche Sequencing Solutions, Inc.

Janssen Pharmaceutica Nv

John Palma

John Lee

Stephanie Yaung

Carlo C Derecho

Mical Raponi

Bernd Hinzmann

Alexander Lovejoy

Ulrich-Peter Rohr

Lijing Yao

Hans-Peter Adams

Aarthi Balasubramanyam

Andre Rosenthal

Urich-Peter Rohr

Fergal Casey

The disclosed method rapidly identifies with desired accuracy AML patients, including elderly AML patients, likely to respond to treatment with a combination of a farnesyltransferase inhibitor and one or more of etoposide, teniposide, tamoxifen, sorafenib, paclitaxel, temozolomide, topotecan, trastuzumab and cisplatinum. In an embodiment, the improvements include the use of whole blood rather than the customary bone marrow sample, thus making the assay more accurate, rapid, less intrusive, less expensive as well as less painful. The method includes evaluation of a two-gene expression ratio (RASGRP1:APTX), which with a corresponding threshold, provides sufficient accuracy for predicting the response to the combination treatment. In the preferred embodiment the combination treatment combines tipifarnib (R115777, ZARNESTRA®) with etoposide. Further, the elderly AML patients identified as being likely responsive to the combination treatment with tipinifarb and etoposide have a complete recovery rate comparable to the best therapy available for younger patients.

Method of determining Acute Myeloid Leukemia response to treatment with farnesyltransferase inhibitors

The invention is a method of predicting response to therapy in a colorectal cancer patient, the method comprising measuring tumor genetic heterogeneity via analysis of circulating tumor DNA from a patients sample.

Method of predicting response to therapy by assessing tumor genetic heterogeneity

The invention is a method of predicting recurrence of colorectal cancer in a patient following surgery, the method comprising analysis of circulating tumor DNA from a patient's sample.

Non-invasive test to predict recurrence of colorectal cancer

The disclosed method rapidly identifies with desired accuracy AML patients, including elderly AML patients, likely to respond to treatment with a combination of a farnesyltransferase inhibitor and one or more of etoposide, teniposide, tamoxifen, sorafenib, paclitaxel, temozolomide, topotecan, trastuzumab and cisplatinum. In an embodiment, the improvements include the use of whole blood rather than the customary bone marrow sample, thus making the assay more accurate, rapid, less intrusive, less expensive as well as less painful. The method includes evaluation of a two-gene expression ratio (RASGRP1:APTX), which with a corresponding threshold, provides sufficient accuracy for predicting the response to the combination treatment. In the preferred embodiment the combination treatment combines tipifarnib (R115777, ZARNESTRA&#xae;) with etoposide. Further, the elderly AML patients identified as being likely responsive to the combination treatment with tipinifarb and etoposide have a complete recovery rate comparable to the best therapy available for younger patients.

Method of determining acute myeloid leukemia response to treatment with farnesyltransferase inhibitors

The invention is a method of predicting response to therapy in a colorectal cancer patient, the method comprising analysis of circulating tumor DNA from a patient's sample.

Non-invasive test to predict response to therapy in colorectal cancer patients

Growing community of inventors

Alamo, CA, United States of America

John Palma